Presentation at Mello2026

Abingdon Health PLC

29 May 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

Presentation at Mello2026

York, UK and Madison, WI, USA, 29 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that Executive Chairman, Chris Hand and CFO, Tom Hayes, will be presenting at the Mello2026 investor event on Tuesday 2 June 2026. The event is taking place at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY. 

Abingdon Health will be presenting twice during the event at 11:35 and 16:10. There will also be opportunity to interact with the management team at the Company's exhibitor stand. For further information and tickets for the Mello2026 conference, please visit the event website at www.melloevents.com/mello2026 (use code SHM2026 for 25% off ticket price).

Any shareholders wishing to keep up to date with Abingdon Health news, please email [e-mail]

Enquiries:

Abingdon Health plc	www.abingdonhealth.com/investors/
Chris Hand, Executive Chairman		Via Walbrook PR
Tom Hayes, CFO
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)		Tel: [phone]
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales)
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.  

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochures outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

LEI - 213800XFI4WV3FBILO20

 

END